Pharma

Your Article Summary

See Latest Articles

Abbotts XIENCE PRIME and XIENCE V Receive Indications in Europe for Treatment of Patients with Diabetes
Abbott, 11/03/09

Abbott announced that both the XIENCE PRIME Everolimus Eluting Coronary Stent System1 and the XIENCE V Everolimus Eluting Coronary Stent System have received additional new CE Markings covering the treatment of patients with diabetes. Receiving these new indications among the European Union Member States validates the use of XIENCE PRIME and XIENCE V to treat patients with diabetes. Coronary artery disease is one of the most common cardiovascular complications of diabetes and is the number one cause of death among European adults with diabetes2.

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09

Huntington Hill Installs Toshiba Aquilion Premium CT
Imaging Economics, 11/25/09

Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09

 See all of Medical Devices/Products